Abstract Background: Aim of this study was to evaluate the activity of a combination regimen of chemotherapy containing mitomycin C (MMC) and etoposide (ETO) in advanced colorectal carcinoma. Methods: Fourteen pretreated patients received MMC 2 mg/m2 and ETO 60 mg/m2, days 1–5 every 28 days. The clinical study was interrupted since no clinical response was observed in 14 patients following four courses of chemotherapy. An in vitro study was then performed on HTC-8 cell line. The cytotoxic activity of the MMC/ETO combination was tested by sulforhodamine B assay and the type of drug interaction was assessed using the method of Chou and Talalay. Cell cycle perturbations and apoptosis were evaluated by flow cytometry. Results: While MMC and ETO were singularly active, the simultaneous exposure of cells to both drugs and the sequence MMC?ETO ensued in antagonistic interaction at all levels of killed cell fraction. Conversely, the sequence ETO?MMC produced a synergistic interaction. Conclusions: These results suggest that the activity of the MMC/ETO combination is highly schedule-dependent and that the experimental drug associations should be based on a preclinical rationale before clinical trials are designed.

Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy / Seminara, Patrizia; Pastore, C; Iascone, Clemente Gilberto; Cicconetti, Franco; Nigita, G; Ielapi, T; Franchi, Fabrizio. - In: CHEMOTHERAPY. - ISSN 0009-3157. - 53:(2007), pp. 218-225. [10.1159/000100872]

Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy

SEMINARA, Patrizia;IASCONE, Clemente Gilberto;CICCONETTI, Franco;FRANCHI, Fabrizio
2007

Abstract

Abstract Background: Aim of this study was to evaluate the activity of a combination regimen of chemotherapy containing mitomycin C (MMC) and etoposide (ETO) in advanced colorectal carcinoma. Methods: Fourteen pretreated patients received MMC 2 mg/m2 and ETO 60 mg/m2, days 1–5 every 28 days. The clinical study was interrupted since no clinical response was observed in 14 patients following four courses of chemotherapy. An in vitro study was then performed on HTC-8 cell line. The cytotoxic activity of the MMC/ETO combination was tested by sulforhodamine B assay and the type of drug interaction was assessed using the method of Chou and Talalay. Cell cycle perturbations and apoptosis were evaluated by flow cytometry. Results: While MMC and ETO were singularly active, the simultaneous exposure of cells to both drugs and the sequence MMC?ETO ensued in antagonistic interaction at all levels of killed cell fraction. Conversely, the sequence ETO?MMC produced a synergistic interaction. Conclusions: These results suggest that the activity of the MMC/ETO combination is highly schedule-dependent and that the experimental drug associations should be based on a preclinical rationale before clinical trials are designed.
2007
Mitomycin C; Etoposide; Drug combination; Colorectal carcinoma
01 Pubblicazione su rivista::01a Articolo in rivista
Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy / Seminara, Patrizia; Pastore, C; Iascone, Clemente Gilberto; Cicconetti, Franco; Nigita, G; Ielapi, T; Franchi, Fabrizio. - In: CHEMOTHERAPY. - ISSN 0009-3157. - 53:(2007), pp. 218-225. [10.1159/000100872]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/239194
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact